ECSP20010477A - Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel - Google Patents

Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel

Info

Publication number
ECSP20010477A
ECSP20010477A ECSENADI202010477A ECDI202010477A ECSP20010477A EC SP20010477 A ECSP20010477 A EC SP20010477A EC SENADI202010477 A ECSENADI202010477 A EC SENADI202010477A EC DI202010477 A ECDI202010477 A EC DI202010477A EC SP20010477 A ECSP20010477 A EC SP20010477A
Authority
EC
Ecuador
Prior art keywords
treatment
chronic skin
pyrphenidone
semi
composition containing
Prior art date
Application number
ECSENADI202010477A
Other languages
English (en)
Inventor
Borunda Juan Socorro Armendariz
Castro Jose Agustin Rogelio Magaña
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Publication of ECSP20010477A publication Critical patent/ECSP20010477A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona composiciones de gel tópicas farmacéuticas para el tratamiento de daños crónicos de la piel, específicamente para los daños causados por úlceras neuropáticas y preferentemente para el tratamiento del pie diabético y en el tratamiento de úlceras vasculares, en donde dichas composiciones comprenden una combinación de Dialil Óxido de Disulfuro Modificado (ODD-M) (como agente antiséptico/antibiótico) y 5-metil-1-fenil-2(1H)-piridona. Además, la invención describe métodos de tratamiento, aplicaciones y/o usos farmacéuticos en la preparación de medicamentos para eliminar, reducir o prevenir lesiones crónicas de la piel y los daños causados por úlceras neuropáticas y particularmente en el tratamiento del pie diabético y en el tratamiento de úlceras vasculares.
ECSENADI202010477A 2017-08-15 2020-02-12 Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel ECSP20010477A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2017010486A MX366086B (es) 2017-08-15 2017-08-15 Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
PCT/MX2018/000071 WO2019035705A2 (es) 2017-08-15 2018-08-10 Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel

Publications (1)

Publication Number Publication Date
ECSP20010477A true ECSP20010477A (es) 2020-04-22

Family

ID=64605095

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202010477A ECSP20010477A (es) 2017-08-15 2020-02-12 Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel

Country Status (15)

Country Link
US (1) US11576905B2 (es)
EP (1) EP3714872A2 (es)
JP (2) JP2020531455A (es)
KR (1) KR102746175B1 (es)
CN (1) CN111246840A (es)
AR (1) AR112474A1 (es)
AU (1) AU2018317188B2 (es)
BR (1) BR112020003001A2 (es)
CA (1) CA3072855A1 (es)
EC (1) ECSP20010477A (es)
MX (1) MX366086B (es)
PH (1) PH12020500324A1 (es)
RU (1) RU2020110783A (es)
SG (1) SG11202002214QA (es)
WO (1) WO2019035705A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
WO2021022033A1 (en) * 2019-07-30 2021-02-04 Leung Kai P Layered composite for scar treatment and prevention
RU2753638C2 (ru) * 2020-01-24 2021-08-18 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") Гелевая композиция для обработки кожных покровов
CN116887810A (zh) * 2020-12-16 2023-10-13 希普拉有限公司 吡非尼酮的局部组合物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
ES421598A1 (es) 1972-12-18 1977-01-01 Affiliated Med Res Un procedimiento para la sintesis de piridonas.
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
DE69618987T2 (de) 1995-12-21 2002-11-21 Pfizer Inc., New York Injizierbare quinolonformulierungen
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
EP1069898B1 (en) 1998-03-17 2004-05-12 MARGOLIN, Solomon B. Topical antiseptic compositions and methods
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
EP1113798B1 (en) * 1998-09-18 2003-01-02 Mepha AG Topical formulation of alkyl-, phenyl-pyridone
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
CH696420A5 (de) * 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
TW200501952A (en) 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
EP1638625A4 (en) 2003-05-23 2009-08-19 David M Ott ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CN100542532C (zh) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
RS53599B1 (sr) 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP1973525B1 (en) 2005-12-05 2014-04-30 RBA Pharma Inc. Emulsion-containing medical articles
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
WO2008107873A1 (en) 2007-03-02 2008-09-12 Yeda Res & Dev Mercaptopurine derivatives as anticancer agents
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
EP2170828B1 (en) 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
EP2245061A2 (en) 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN101972225A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
CA2824432C (en) 2011-01-31 2021-10-19 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN102670632A (zh) * 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX2012003874A (es) 2012-03-30 2012-11-19 Moleculas Naturales S A De C V Procedimiento para la obtencion del complejo de cloruro de benzalconio-dialil oxido de disulfuro modificado en uso como biocida.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
WO2017104725A1 (ja) 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Also Published As

Publication number Publication date
KR102746175B1 (ko) 2024-12-26
CA3072855A1 (en) 2019-02-21
BR112020003001A2 (pt) 2020-08-11
US11576905B2 (en) 2023-02-14
AR112474A1 (es) 2019-10-30
SG11202002214QA (en) 2020-04-29
MX366086B (es) 2019-06-27
AU2018317188B2 (en) 2024-08-29
WO2019035705A3 (es) 2019-05-09
WO2019035705A2 (es) 2019-02-21
JP2020531455A (ja) 2020-11-05
EP3714872A2 (en) 2020-09-30
RU2020110783A3 (es) 2021-12-08
RU2020110783A (ru) 2021-09-16
PH12020500324A1 (en) 2020-09-28
KR20200091379A (ko) 2020-07-30
AU2018317188A1 (en) 2020-04-02
JP2023080289A (ja) 2023-06-08
MX2017010486A (es) 2018-09-21
US20200253944A1 (en) 2020-08-13
CN111246840A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
ECSP20010477A (es) Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel
MX2020010405A (es) Composicion para el tratamiento de heridas cronicas.
CL2019002959A1 (es) Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718).
MX338611B (es) Una composicion farmaceutica sinergistica novedosa para aplicaciones topicas.
MX2017014804A (es) Composiciones farmaceuticas topicas.
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
CO6460708A2 (es) Composiciones borínicas
CU20140114A7 (es) Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
PH12017501133A1 (en) Pyrazolopyridinamines
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
CU24390B1 (es) Piperidinil-tetrahidroquinolinas sustituidas
FR2978665B1 (fr) Composition antiseptique
AR092199A1 (es) Composicion antiseptica, antiseborreica y exfoliante para eliminar o prevenir el acne
MX378164B (es) Amidas aromaticas de acido carboxilico.
UY36273A (es) Composicion para el tratamiento de neuropatías y del dolor neuropático
PE20150755A1 (es) Formulacion transdermica que contiene inhibidores de cox
UA113151C2 (xx) Застосування композиції, що містить антимікробний поліпептид, у виробництві лікарського засобу
MX373977B (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
MX2020010747A (es) Formulaciones topicas que comprenden estroncio y metilsulfonilmetano (msm) y metodos de tratamiento.
MX2018000538A (es) Composicion antimicrobiana.
ECSP21027009A (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
MX2025013387A (es) Formulaciones de pectolinarigenina